Table 2.
Protective efficacy of recombinant protein against challenge infection with E. magna
| Groups | Average weight gain before challenge/g | Average weight gain after challenge/g | Relative weight gain ratio (%) | Oocyst output (× 104) | Oocyst reduction ratio (%) | Mean lesion scores | ACI | Feed conversion ratio |
|---|---|---|---|---|---|---|---|---|
| Unchallenged control | 631.25 ± 51.46a | 421.88 ± 38.26a | NA | NA | NA | 0 | 200 | 3.31:1 |
| Challenged control | 612.50 ± 94.11a | 204.37 ± 48.44b | 40.59 | 2.81 ± 1.19a | NA | 1.25 | 88.09 | 6.85:1 |
| Adjuvant control | 647.50 ± 123.4a | 202.50 ± 73.96b | 48.00 | 2.84 ± 0.83a | − 1.17 | 1.37 | 94.25 | 6.91:1 |
| Vector protein | 606.87 ± 94.33a | 198.75 ± 79.40b | 47.11 | 2.78 ± 0.81a | 1.06 | 1.12 | 95.86 | 7.04:1 |
| rEmMIC2 | 646.25±84.92a | 330.62±83.51c | 78.37 | 0.62 ± 0.52b | 77.95 | 0.62 | 171.12 | 4.23:1 |
| rEmMIC3 | 603.75±92.34a | 317.50±99.13c | 75.29 | 0.67 ± 0.60b | 76.09 | 0.5 | 169.29 | 4.40:1 |
Values represent the mean ± S.D. of 8 rabbits. Statistical significances between the means of different treatment groups were analyzed with SPSS software, and a significant difference was considered at P < 0.05. In the same column, a significant difference (P < 0.05) between groups was shown with different letters, and no significant difference (p > 0.05) between groups was shown with the same letter